Activest Wealth Management’s Iterum Therapeutics ITRM Stock Holding History

Activest Wealth Management’s Portfolio ITRM Stock Details ITRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-133	Closed	-$4	–	1428
2026 Q1	$4	Hold	133	–	–	﹤0.01%	1224
2025 Q4	$45	Hold	133	–	–	﹤0.01%	1087
2025 Q3	$89	Hold	133	–	–	﹤0.01%	1068
2025 Q2	$132	Hold	133	–	–	﹤0.01%	961
2025 Q1	$164	Hold	133	–	–	﹤0.01%	941
2024 Q4	$235	Hold	133	–	–	﹤0.01%	622
2024 Q3	$145	Hold	133	–	–	﹤0.01%	518
2024 Q2	$152	Buy	+133	New	+$193	﹤0.01%	490

Other funds holding ITRM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

CCMW

Cypress Capital Management (Wyoming) Sheridan, Wyoming $120M AUM 63.01% 1-Year Est. Return

Activest Wealth Management's ITRM Position: Q2 2026 in Review

Activest Wealth Management sold out of Iterum Therapeutics (ITRM) in Q2 2026, closing a stake of 133 shares — an estimated $4 sold.

Activest Wealth Management first reported a position in ITRM in Q2 2024 and held it in 8 quarters. The position peaked at $235 in Q4 2024. 2 funds tracked by Wall St. Rank hold ITRM as of Q2 2026.

Activest Wealth Management reported no remaining Iterum Therapeutics position as of Q2 2026 after selling out during the quarter.
Activest Wealth Management sold 133 Iterum Therapeutics shares in Q2 2026, an estimated $4.
Activest Wealth Management first reported a position in Iterum Therapeutics in Q2 2024 and held it in 8 quarters.
Activest Wealth Management's Iterum Therapeutics position peaked at $235 in Q4 2024.
2 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2026.

Based on Activest Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.